(Circulation. 1999;99:2164-2170.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle
From the Cardiovascular Biology Research Laboratory, the Zena and Michael Wiener Cardiovascular Institute (R.G., A.P., M.R., J.C., J.F., V.F., J.J.B.), and the Department of Pathology (J.F.), Mount Sinai School of Medicine, New York, NY; the Molecular Cardiology Program, Columbia University, College of Physicians and Surgeons, New York, NY (T.J., S.M., A.M.); and Wyeth-Ayerst, Princeton, NJ (S.A.).
Correspondence to Juan José Badimon, PhD, Cardiovascular Biology Research Laboratory, Zena and Michael Wiener Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY-10029. E-mail jjb-laboratory{at}smtplink.mssm.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Although percutaneous transluminal coronary angioplasty (PTCA) is a highly effective procedure to reduce the severity of stenotic coronary atherosclerotic disease, its long-term success is significantly limited by the high rate of restenosis. Several cellular and molecular mechanisms have been implicated in the development of restenosis post-PTCA, including vascular smooth muscle cell (VSMC) activation, migration, and proliferation. Recently, our group demonstrated that rapamycin, an immunosuppressant agent with antiproliferative properties, inhibits both rat and human VSMC proliferation and migration in vitro. In the present study, we investigated (1) whether rapamycin administration could reduce neointimal thickening in a porcine model of restenosis post-PTCA and (2) the mechanism by which rapamycin inhibits VSMCs in vivo.
Methods and Results—PTCA was performed on a porcine model at a balloon/vessel ratio of 1.7±0.2. Coronary arteries were analyzed for neointimal formation 4 weeks after PTCA. Intramuscular administration of rapamycin started 3 days before PTCA at a dose of 0.5 mg/kg and continued for 14 days at a dose of 0.25 mg/kg. Cyclin-dependent kinase inhibitor (CDKI) p27kip1 protein levels and pRb phosphorylation within the vessel wall were determined by immunoblot analysis. PTCA in the control group was associated with the development of significant luminal stenosis 4 weeks after the coronary intervention. Luminal narrowing was a consequence of significant neointimal formation in the injured areas. Rapamycin administration was associated with a significant inhibition in coronary stenosis (63±3.4% versus 36±4.5%; P<0.001), resulting in a concomitant increase in luminal area (1.74±0.1 mm2 versus 3.3±0.4 mm2; P<0.001) after PTCA. Inhibition of proliferation was associated with markedly increased concentrations of the p27kip1 levels and inhibition of pRb phosphorylation within the vessel wall.
Conclusions—Rapamycin administration significantly reduced the arterial proliferative response after PTCA in the pig by increasing the level of the CDKI p27kip1 and inhibition of the pRb phosphorylation within the vessel wall. Therefore, pharmacological interventions that elevate CDKI in the vessel wall and target cyclin-dependent kinase activity may have a therapeutic role in the treatment of restenosis after angioplasty in humans.
Key Words: restenosis • cells • angioplasty
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Vascular smooth muscle cell (VSMC) proliferation and migration contribute significantly to the restenotic process after percutaneous transluminal coronary angioplasty (PTCA) and accelerated arteriosclerosis after cardiac transplantation. Long-term success is limited by the high rate of restenosis, which affects
40% to 50% of the
patients undergoing PTCA.1 2 3 Pathological, clinical, and
experimental evidence suggests that multiple cellular and molecular
mechanisms are involved in a cascade of events that lead to
restenosis. Autocrine and paracrine mediators triggered by the
coronary intervention induce arterial narrowing as
a result of the increased VSMC proliferation and synthesis of
extracellular matrix.4 5 6 Attention has been focused on
elucidating the mechanisms underlying VSMC proliferation with the goal
of developing therapeutic approaches to inhibit restenosis
after PTCA.7 8 9 Arterial injury during PTCA induces multiple signaling pathways that activate VSMC migration and proliferation. Immediately after injury, VSMCs leave their quiescent state and enter the cell cycle, associated with the induction of early-response genes.10 11 12 Cell division and growth are tightly controlled by a series of positive and negative regulators that act at sequential points throughout the cell cycle. Studies show that antisense oligonucleotides targeted to cyclin-dependent kinases (cdc2 and cdk2) can be effective in inhibiting VSMC proliferation and restenosis.7 9 13 14 Recently, our group and others identified the tumor suppressor protein retinoblastoma protein (pRb) as a critical regulator of VSMC proliferation.15 16 Phosphorylation and inactivation of pRb in response to mitogenic stimulation results in G1/S transition and proliferation. The inhibition of pRb phosphorylation by either antisense oligonucleotides to cyclin-dependent kinases (CDK)7 10 or pharmacological agents such as rapamycin8 results in cell-cycle arrest in VSMCs and inhibition of proliferation.
The kinase activity of the cyclin/CDK complex is regulated by their interaction with inhibitors (CDKI), such as p16, p21, and p27kip1.15 16 CDKIs act stoichiometrically, and oscillations in their levels profoundly impact cell-cycle progression. In a rat carotid model of balloon angioplasty, adenovirus-mediated overexpression of the CDKI p21 inhibited pRb phosphorylation and VSMC proliferation.13 14 p27kip1 levels are increased in response to serum deprivation, cell-cell contact, or transforming growth factor-ß (TGF-ß).15 16 The downregulation of p27kip1 by mitogens is blocked with rapamycin.17 Defective regulation of p27kip1, either secondary to constitutively low levels of p27kip1 or due to a targeted disruption of the p27kip1 gene (p27 knockout mouse), results in rapamycin resistance.
Recently, Marx et al8 reported that rapamycin, a macrolide antibiotic, inhibited both human and rat VSMC proliferation in vitro by blocking G1/S transition. The inhibition of proliferation was mediated by rapamycin binding to its cytosolic receptor, FKBP12, and associated with reduced cdc2 and cdk2 activity and pRb phosphorylation.8 In addition, rapamycin inhibits rat, porcine, and human VSMC migration.18 Rapamycin also prevents the downregulation of p27kip1 in a myogenic cell line, BC3H1,17 thus contributing to cell-cycle arrest. The observation that rapamycin blocks VSMC proliferation and migration in vitro suggests that rapamycin could prevent VSMC activation after PTCA regardless of the mechanism(s) that initiates the process. Several studies suggested that rapamycin, but not FK506, retards the development of graft vessel disease after cardiac transplantation and restenosis after mechanical injury in rat.19 20
In the present study, we investigated whether rapamycin effectively interferes with the pathological proliferative response after coronary angioplasty in swine. Our results indicate that rapamycin reduced intimal thickening by 50% after coronary angioplasty. This effect is marked by a selective inhibition of the VSMC proliferative response to coronary injury associated with decreased pRb phosphorylation and elevated levels of p27kip1 causing cell-cycle arrest at G1/S. Thus, like adenovirus-mediated overexpression of a CDKI, we demonstrate that a pharmacological approach to elevate a CDKI in the coronary arteries results in the inhibition of restenosis after PTCA.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animal Species
The study used Yorkshire-Albino swine (27 to 32 kg body weight). Interventional procedures and animal handling were approved by the Mount Sinai School of Medicine Animal Management Program, which is accredited by the American Association for the Accreditation of Laboratory Animal Care and meets NIH and AHA standards.
Experimental Design
Rapamycin (Sirolimus) was a gift from Wyeth-Ayerst Research
Laboratory (Dr Suren Sehgal). Despite its oral bioavailability,
rapamycin was administered intramuscularly to ensure stable blood
levels. Rapamycin administration was started 3 days before angioplasty
at a dose of 0.5 mg/kg and continued for 14 days at a dose of 0.25
mg/kg. Before administration, rapamycin was suspended in a sterile
solution containing 0.2% sodium carboxymethyl cellulose and 0.25%
polysorbate-80. The control group received the vehicle solution.
Coronary balloon angioplasty was carried out in the pigs as previously reported.21 All pigs were anticoagulated with heparin (100 IU/kg) after insertion of the catheters. This anticoagulation regimen attained an activated partial thromboplastin time ratio 2 to 3 times control. PTCA was performed by 3 inflations at 8 to 10 atm of a 4-mm balloon for 15 seconds with 60-second rest periods between inflations. After the angioplasty procedure, the animals were allowed to recover, returned to their pens, and followed up for 28 days.
Fixation, Harvesting, and Pathological Evaluation of Injured
Vessels
Animals were deeply anesthetized, fully heparinized (100
U/kg), euthanatized, and perfusion-fixed at 100 mm Hg with 1 L
cold (4°C) 4% paraformaldehyde in 0.1 mol/L PBS, pH
7.4, as reported.21 After perfusion fixation, the
coronary arteries of interest were excised, immersed in fresh
fixative, and cross-sectioned at 2-mm intervals. Specimens were
paraffin-embedded (at 59°C), sectioned (5 µm), and stained by
the combined Masson elastin method.
Histomorphometric Analysis
All 2-mm coronary segments were evaluated by 2
experienced observers blinded to the treatment group. For each
angioplastied coronary artery, the section with the most
extensive injury-induced response was identified and evaluated as
reported.21 A total of 17 coronary arteries from
10 animals in the rapamycin-treated group and 22 coronary
arteries from 10 animals in the control group were studied.
The neointima was subdivided into 3 distinct areas that were clearly visible by direct histological examination. These 3 areas were defined as organizing thrombus, submedial hematoma, and fibrocellular hyperplasia. Organizing thrombus was defined as remnants of an original thrombus induced at the time of angioplasty and undergoing organization. It was usually observed beneath or within the proliferative lesion present between the breaks in the internal elastic lamina and media. Submedial hematoma was defined as a clot formed under medial flaps or dissections. Fibrocellular hyperplasia was defined as those areas composed solely of cellular elements and extracellular matrix.
Measurements of Retinoblastoma Protein and p27kip1
Levels
Rb phosphorylation and
p27kip1 in the vessel wall were determined as
previously described.8 22 Briefly, arterial
tissues were homogenized with a tissue blender in a lysis
buffer. Protein extracts (300 µg) were size-fractionated on 12%
SDS-polyacrylamide gels, transferred to nitrocellulose
overnight. Filters were incubated overnight with an affinity-purified
polyclonal antibody to Rb (Pharmingen) and p27 (Santa Cruz
Biotechnology; sc-528), respectively. Membranes were washed 4 times
with Tris-buffered saline containing 0.1% Tween-20 and incubated with
the secondary antibody (goat anti–mouse IgG for pRb and goat
anti–rabbit IgG for p27) (1:1000) for 1 hour. The membranes were
washed and the signals detected by the ECL chemiluminescence detection
system (Amersham). Autoradiographic signals are quantified
by densitometry.
Statistical Analysis
Data are presented as mean±SEM unless otherwise stated.
Absolute areas are expressed as mm2. The
statistical significance of differences between the normal and treated
groups was determined by a 1-way ANOVA. Differences were considered
significant if P<0.05 by use of StatView 512+ statistical
software (Brain Power, Inc).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Arterial Injury Induced by the Angioplasty Procedure
All coronary segments analyzed for intimal proliferation after angioplasty were histologically characterized by disruption of the internal elastic lamina, with laceration of the tunica media and exposure of the external elastic lamina. The degree of arterial injury induced by the coronary intervention was similar in both groups. The average balloon/vessel ratio was 1.5±0.2 versus 1.5±0.1 in the control and rapamycin-treated animals, respectively.
Intimal Proliferation After Arterial Injury
At death, 4 weeks after angioplasty, both groups of animals
showed a similar coronary size, assessed by the vascular area
encircled by the external elastic lamina (7.3±0.5 versus 7.6±0.4
mm2 for the rapamycin and the control group,
respectively). When the luminal area was evaluated, a statistically
significantly larger lumen was observed in the rapamycin-treated
animals compared with the controls (3.3±0.4 versus 1.74±0.1
mm2, respectively; P<0.0001) (Figure 1A
). The significant luminal narrowing in
the control group resulted from a larger standardized intimal-medial
ratio (4.0±0.8 controls versus 1.9±0.4 rapamycin;
P<0.001) (Figure 1B), which indicated a reduced
proliferative response to angioplasty-induced arterial
injury in the treated group.
|
Coronary Stenosis
Results of the average values of coronary
stenosis induced by balloon angioplasty 4 weeks after
intervention are presented in Figure 2. Representative
photomicrographs of histological sections from the
control and rapamycin-treated groups are depicted in Figure 3. These figures show a significant
intimal proliferation in the control arteries. The newly formed
proliferative tissue, characterized by spindle-shaped cells, filled
gaps between medial tears and generally extended to adjacent medial
areas encroaching into the lumen. The administration of rapamycin was
associated with a significant reduction in the percentage of luminal
stenosis induced by the angioplasty (36±4.5% versus
63±3.4%, control versus rapamycin; P<0.0001). Total
stenosis was subdivided into its 3 major components: residual
thrombus, organizing hematoma, and fibrocellular hyperplasia. No
statistically significant differences were observed in the percentage
of either residual thrombus (12.3±2.3% versus 9.2±1.8%, controls
versus rapamycin, respectively) or hematoma (6.6±1.5% versus
6.1±2.2%, controls versus rapamycin). In contrast, there was a marked
reduction in the percentage of fibrocellular hyperplasia (43.8±2.2%
versus 21.0±3.1%, controls versus rapamycin; P<0.0001).
This finding indicates that the inhibitory effect of
rapamycin on intimal proliferation after coronary angioplasty
was mediated through specific inhibition of VSMC proliferation.
|
|
Vessel Wall p27kip1 Protein Determination
In various cell types, the decrease in p27 levels on addition of
mitogens activates CDKs, leading to pRb
hyperphosphorylation and cell-cycle progression and
proliferation.22 To demonstrate that the effect of
rapamycin on SMC proliferation was mediated by this mechanism, we
examined the level of p27kip1 in the vessel wall
of animals undergoing balloon angioplasty treated with rapamycin or
vehicle. Administration of rapamycin resulted in a significant increase
in p27kip1 at the selected time points of 3 and
15 days after PTCA (Figure 4). These time
points were selected on the basis of previously reported data in
different animal models suggesting that cell proliferation peaks within
the first 3 days postintervention and that the 15-day point
corresponded to the end of therapy administration. Therefore, rapamycin
administration prevents the downregulation of the CDKI
p27kip1 in the vessel wall post-PTCA in the pig.
Thus, pharmacological manipulation of CDKI levels results in inhibition
of VSMC proliferation.
|
Vessel Wall Retinoblastoma Protein Phosphorylation
We also analyzed the effects of rapamycin administration
on the Rb phosphorylation in the coronary wall
after angioplasty. Immunoblot analysis of pRb
protein levels in coronary arteries of rapamycin-treated and
control animals is presented in Figure 5. Figure 5 shows the
inhibitory effects of rapamycin on the
phosphorylation of the pRb, as indicated by the
presence of a lower band corresponding to the
underphosphorylated Rb (pRB). Conversely, the
vehicle-treated coronary arteries showed 1 single band
corresponding to the hyperphosphorylated pRb (ppRb).
Our observations indicate that rapamycin also interferes with the
phosphorylation of the Rb protein.
|
Rapamycin Blood Levels
A loading dose of 0.5 mg ·
kg-1 · d-1 for 3
days before PTCA attained plasma levels of 57 ng/mL of blood at the
time of the coronary intervention. The administration of a
lower maintenance dose (0.25 mg ·
kg-1 · d-1)
maintained similar blood levels (59±12 ng/mL) at day 14 after PTCA.
Interestingly, 14 days after the last rapamycin injection, the average
level of rapamycin was 36±3 ng/mL of blood. These pharmacokinetic
observations indicate that the biodistribution of this compound is
associated with a depot effect when administered intramuscularly that
might account for the prolonged blood residence time of this compound.
No correlation was found between individual rapamycin blood levels and
the corresponding values of intimal thickening, suggesting that the
lower blood concentrations were as effective as the higher ones.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study demonstrates that rapamycin inhibits intimal proliferation after PTCA in the pig model. Our results show a 50% reduction in fibrocellular hyperplasia in the rapamycin-treated animals compared with controls. The observed antiproliferative effect of rapamycin is associated with an inhibition of the pRB phosphorylation and increase in CDKI p27kip1 levels. These findings suggest that rapamycin could serve as a new therapeutic approach to reduce human restenosis after PTCA. The use of a pharmacological agent specifically targeted to elevate the level of a CDKI within the vessel wall represents a novel approach in the prevention of restenosis.
Rapamycin, a macrolide antibiotic with antifungal and immunosuppressive activities, inhibits the development of arteriopathy after allograft transplantation.19 20 23 The drug is currently in phase II and III clinical trials in liver, kidney, and heart transplantation. Rapamycin exerts its antiproliferative activity after binding to the cytosolic protein FKBP12.24 The FKBP12-rapamycin complex is an inhibitor of a 289-kDa protein named FRAP or RAFT1, which is a member of a newly discovered family of phosphatidylinositol kinase–related kinases.25 Furthermore, rapamycin inhibits translation of a subset of mRNA that is believed to be critical for G1 progression.16 Increased p27 levels cause inhibition of CDK activity, which leads to the inhibition of pRb phosphorylation in vivo. The underphosphorylated form of pRb is believed to be a functionally active form of pRb in G0/mid G1.26 It is proposed that pRb forms complexes while underphosphorylated with DNA-binding proteins, such as E2F. On pRb phosphorylation, unbound E2F appears to stimulate transcription of cellular genes implicated in induction of the S phase.27 Thus, inhibition of pRb hyperphosphorylation by rapamycin interferes with cell-cycle signaling and cell proliferation
Severe arterial injury in the swine model, whether induced
by PTCA or stent implantation, triggers a hyperplastic response
characterized by the development of intimal thickening in the injured
arterial segments. Similar results have been described by
others.28 29 In all instances, the greatest proliferative
response occurs at the sites of maximal injury (Figure 3
). In
our study, the severity of the arterial injury induced by
the angioplasty procedure was similar in the 2 groups of animals, as
shown by the damage index and the percentage of missing internal
elastic lamina. Because there was no difference in the degree of
arterial injury between control and rapamycin-treated
animals, the observed reduction in luminal narrowing was a consequence
of the treatment and the elevation of the CDKI
p27kip1 in the vessel wall.
The proliferative response after PTCA observed in the control group was
clearly manifested by the thickening of the intimal layer and a
reduction in the coronary lumen as shown in Figures 2 and 3. The rapamycin-treated animals exhibited a significantly
larger lumen compared with the controls, as well as a reduction in
intimal thickening. Animals receiving rapamycin showed an 50%
decrease in the fibrocellular response (41.2±2.3% controls versus
21.0±3.1% rapamycin animals; P<0.0001). No differences
were observed in the contribution of residual thrombus or hematoma to
total luminal stenosis. The significant inhibition in
fibrocellular hyperplasia supports in vitro data demonstrating that
rapamycin inhibits SMC proliferation and
migration.8 18
Administration of rapamycin was initiated 3 days before angioplasty to ensure that VSMCs would be maintained in a quiescent state from the moment of injury. Rapamycin administration was then maintained for an additional 14 days to prevent any growth stimulus that might occur during the subsequent 2 weeks after the procedure. This regimen attained significant blood levels even 14 days after the last rapamycin administration. This longer blood residence time might also be important to the observed inhibitory effect on neointimal formation after PTCA.
The antiproliferative activity of rapamycin in conjunction with its immunosuppressive properties suggests that this drug could also be useful for the prevention and/or treatment of accelerated arteriopathy associated with organ transplantation, particularly in the case of cardiac transplantation, in which accelerated arteriopathy is a major cause of mortality and morbidity and the need for repeat transplantation.
After arterial injury, multiple mitogenic and proliferative factors have been identified as capable of triggering signaling mechanisms leading to SMC activation.4,30,31 Numerous pharmacological agents, including antiplatelet agents, anticoagulants, ACE inhibitors, and cytotoxic agents, have not significantly reduced restenosis after angioplasty.32 33 34 35 However, because rapamycin inhibits multiple regulators of cell-cycle progression in VSMCs, its mechanism of action differs from many of these agents. Moreover, the ability of rapamycin to inhibit in vitro VSMC proliferation in rodents, humans,8 19 and now in vivo in pigs suggests that its efficacy, unlike many other antiproliferative agents that have failed in human trials, is not species-specific.
Numerous studies have reported beneficial effects of gene-based therapy to inhibit restenosis after PTCA. Delivery of antisense oligonucleotides to c-myb, cdc2, and PCNA or cdk2 have been reported to inhibit restenosis in the rat carotid artery model.7 36 However, there are several disadvantages with the use of antisense technology, including nonspecific effects, batch variability, and difficulty with the delivery system.37 38 39 In addition, adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene followed by administration of ganciclovir has been shown to inhibit restenosis in rat and pig.40 41 42 Several disadvantages of this approach include the induction of cell death, which may lead to intravascular inflammation and the potential for medial necrosis and aneurysm formation, as well as side effects of ganciclovir therapy.13 14 Another approach used was the adenovirus-mediated overexpression of either a nonphosphorylatable constitutively active form of pRb9 or the overexpression of the CDKI p21.13 14 Because rapamycin can be administered orally and causes the inhibition of pRb phosphorylation, as well as increased levels of the CDKI p27kip1 in the vessel wall, rapamycin may be an ideal agent to inhibit restenosis post-PTCA.
In summary, our study demonstrates that rapamycin significantly reduces the proliferative response after coronary angioplasty in the pig. Because rapamycin targets fundamental regulators of cell growth, its ability to inhibit experimental stenosis in the pig coronary model suggests that these regulators play a significant role in the pathogenesis of injury-induced intimal thickening. Moreover, these results suggest that administration of rapamycin to patients post-PTCA may have a role in the inhibition of restenosis.
|
Acknowledgments |
|---|
This work was supported by grants from the NIH, P50-HL-54469 (Dr Badimon); RO1-AI-39794 and HL-56180 (Dr Marks), Grants-in-Aid from the American Heart Association (Drs Jayaraman and Marks), a New Investigator Development Award from the AHA New York Chapter (Dr Jayaraman), and a grant from Wyeth-Ayerst. Dr Marks is a Bristol-Meyers Squibb Established Investigator of the AHA. The authors would like to thank Eduardo Acampado, DVM, and Veronica Gulle for their technical assistance, the CLAS personnel, and especially Russell Jenkins and Gladys Volmar, for their collaboration in the preparation, handling, and supervision of the animals.
Received June 5, 1998; revision received November 30, 1998; accepted December 18, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Popma J, Califf R, Topol E. Clinical trials of restenosis after PTCA. Circulation. 1991;84:1426–1436.
2.
Landau C, Lange R, Hillis L.
Percutaneous transluminal coronary angioplasty.
N Engl J Med. 1994;330:981–993.
3. Fuster V, Falk E, Fallon J, Badimon L, Chesebro J, Badimon JJ. The three processes leading to post PTCA restenosis: dependence on the lesion substrate. Thromb Haemost. 1995;74:552–559.[Medline] [Order article via Infotrieve]
4. Foegh M, Virmani R. Molecular biology of intimal proliferation. Curr Opin Cardiol. 1993;8:938–955.
5.
Gorski D, LePage D, Patel C, Copeland N, Jenkins N,
Walsh K. Molecular cloning of a diverged homeobox gene that is rapidly
down-regulated during the
G0/G1 transition in VSMC.
Mol Cell Biol. 1993;13:3722–3733.
6. Cascells W, Lappi D, Bird A. Molecular atherectomy for restenosis. Trends Cardiovasc Med. 1993;156:48–55.
7. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von der Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau V. Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin Invest. 1994;93:1458–1464.
8.
Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP
inhibits cell cycle regulators of proliferation in VSMC. Circ
Res. 1995;76:412–417.
9.
Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel
EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular
proliferative disorders with a constitutively active form of the
retinoblastoma gene product. Science. 1995;267:518–522.
10. Serrano M, Hannon GH, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–707.[Medline] [Order article via Infotrieve]
11. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 CDK-interacting protein cip1 is a potent inhibitor of cyclin kinases. Cell. 1993;75:805–816.[Medline] [Order article via Infotrieve]
12. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59–66.[Medline] [Order article via Infotrieve]
13. Chang M, Barr E, Lu M, Barton K, Leiden J. Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular SMC proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260–2268.
14. Chen D, Krasinki K, Chen D, Sylvester A, Nisen PD, Andres V. Down-regulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in VSMC by p27, an inhibitor of neointima formation in the rat carotid artery. J Clin Invest. 1997;99:2334–2341.[Medline] [Order article via Infotrieve]
15.
Reynisdottir I, Polyak K, Iavaronne A, Massague J.
Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell
cycle arrest in response to TGF-ß. Genes Dev. 1995;9:1831–1845.
16. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts JM. Interleukin-2 mediated elimination of the p27 kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature (Lond). 1994;372:570–573.[Medline] [Order article via Infotrieve]
17. Luo Y, Marx SO, Kiyokawa H, Koff A, Massague J, Marks AR. Rapamycin resistance tied to defective regulation of p27kip1. Mol Cell Biol. 1996;16:6744–6751.[Abstract]
18. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits VSMC migration. J Clin Invest. 1996;98:2277–2283.[Medline] [Order article via Infotrieve]
19. Gregory C, Huie P, Billingham M, Morris R. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Transplantation. 1993;55:1409–1418.[Medline] [Order article via Infotrieve]
20. Meiser B, Billingham M, Morris R. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet. 1991;338:1297–1298.[Medline] [Order article via Infotrieve]
21.
Gallo R, Padurean A, Toschi V, Bichler J, Fallon J,
Chesebro J, Fuster V, Badimon J. Prolonged thrombin inhibition reduces
restenosis after balloon angioplasty in porcine
coronary arteries. Circulation. 1998;97:581–588.
22.
Jayaraman T, Marks AR. Rapamycin-FKBP blocks
proliferation, induces differentiation and inhibits cdc2 kinase
activity in a myogenic cell line. J Biol Chem. 1993;268:25385–25388.
23. Almond PS, Moss A, Nakhleh RE, Melin M, Chen S, Salazar A, Chirabe K, Matas AJ. Rapamycin: immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model. Transplantation. 1993;56:275–281.[Medline] [Order article via Infotrieve]
24.
Schreiber S. Chemistry and biology of the immunophilins
and their immunosuppressive ligands. Science. 1991;251:283–287.
25. Brown EJ, Schreiber S. A signaling pathway to control translational control. Cell. 1996;86:517–520.[Medline] [Order article via Infotrieve]
26. Chen PL, Scully P, Shew JY, Want JY, Lee WH. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell. 1989;58:1193–1198.[Medline] [Order article via Infotrieve]
27. Cordon C. Mutation of cell cycle regulators. Am J Pathol. 1995;147:545–560.[Abstract]
28. Muller DW, Ellis S, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418–432.[Abstract]
29.
Schwartz RS, Murphy JG, Edwards WD, Camrud AR,
Vlietstra RE, Holmes DR. Restenosis after PTCA: a practical
proliferative model in porcine coronary arteries.
Circulation. 1990;82:2190–2200.
30. Fuster V, Badimon L, Badimon JJ, Ip J, Chesebro JH. The porcine model for the understanding of thrombogenesis and atherogenesis. Mayo Clinic Proc. 1991;66:818–831.[Medline] [Order article via Infotrieve]
31. Wilcox JN. Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. Am J Cardiol. 1993;72:88E–95E.[Medline] [Order article via Infotrieve]
32. Muller DW, Ellis SG, Topol EJ. Colchicine and antineoplastic therapy for the prevention of restenosis after PTCA. J Am Coll Cardiol. 1991;17:126B–131B.
33.
Thornton MA, Gruentzig A, Hollman J, King S, Douglas J.
Coumadin and aspirin in prevention of recurrence after PTCA: a
randomized trial. Circulation. 1984;69:721–727.
34.
Group MS. Does the new angiotensin
converting enzyme inhibitor cilazapril prevent
restenosis after PTCA? Results of the MERCATOR study.
Circulation. 1992;86:100–110.
35. Ellis SG, Roubin G, Wilentz J, Douglas J, King SB. Effect of the 18–24 hour heparin administration for prevention of restenosis after uncomplicated PTCA. Am Heart J. 1989;117:777–782.[Medline] [Order article via Infotrieve]
36. Simons M, Edelman ER, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial SMC accumulation in vivo. Nature. 1992;359:67–70.[Medline] [Order article via Infotrieve]
37.
Villa AE, Guzman LA, Garrel CL, Poptic EJ, Labhasetwar
V, DiSousa S, Farrell CL, Plow EF, Levy RJ, DiCorleto PE, Topol EJ.
Effects of antisense c-myb oligonucleotides
on VSMC proliferation and response to arterial wall injury.
Circ Res. 1995;76:505–513.
38.
Stein CA, Cheng Y-C. Antisense
oligonucleotides as therapeutic agents: is the bullet
really magical? Science. 1993;261:1004–1012.
39.
Epstein SE, Speir E, Finkel T. Do antisense approaches
to the problem of restenosis make sense?
Circulation. 1993;88:1351–1353.
40.
Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG,
Epstein SE, Finkel T. In vivo suppression of injury-induced
VSMC accumulation using adenovirus-mediated transfer of the herpes
simplex virus thymidine kinase gene. Proc Natl Acad Sci
U S A. 1994;91:10732–10736.
41. Chang MW, Ohno T, Gordon D, Lu MN, Nabel GJ, Nabel EJ, Leiden JM. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits VSMC proliferation and neointima formation following angioplasty of the rat carotid artery. Mol Med. 1995;1:172–181.[Medline] [Order article via Infotrieve]
42.
Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ,
Nabel GJ, Nabel EJ. Gene therapy for VSMC proliferation after
arterial injury. Science. 1994;265:781–784.
This article has been cited by other articles:
 |
|
 |
|
  A.-L. RIVAL-TRINGALI, S. EUVRARD, E. DECULLIER, A. CLAUDY, M. FAURE, and J. KANITAKIS Conversion from Calcineurin Inhibitors to Sirolimus Reduces Vascularization and Thickness of Post-transplant Cutaneous Squamous Cell Carcinomas Anticancer Res, June 1, 2009; 29(6): 1927 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Suzuki, A. C. Yeung, and F. Ikeno The Pre-Clinical Animal Model in the Translational Research of Interventional Cardiology J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 373 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Morello, A. Perino, and E. Hirsch Phosphoinositide 3-kinase signalling in the vascular system Cardiovasc Res, May 1, 2009; 82(2): 261 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Peyton, D. Ensenat, M. A. Azam, A. N. Keswani, S. Kannan, X.-m. Liu, H. Wang, D. A. Tulis, and W. Durante Arginase Promotes Neointima Formation in Rat Injured Carotid Arteries Arterioscler. Thromb. Vasc. Biol., April 1, 2009; 29(4): 488 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mutsuga, Y. Narita, A. Yamawaki, M. Satake, H. Kaneko, Y. Suematsu, A. Usui, and Y. Ueda A new strategy for prevention of anastomotic stricture using tacrolimus-eluting biodegradable nanofiber. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 703 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shan, T. B. Nguyen, H. Totary-Jain, H. Dansky, S. O. Marx, and A. R. Marks Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors PNAS, December 2, 2008; 105(48): 19006 - 19011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Costa Jr, A. Abizaid, R. Costa, F. Feres, L. F. Tanajura, A. Abizaid, L. A. Mattos, R. Staico, D. Siqueira, A. G.M.R. Sousa, et al. Preliminary Results of the Hydroxyapatite Nonpolymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions: A First-in-Human Analysis of a Third-Generation Drug-Eluting Stent System J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 545 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ferri, A. Granata, C. Pirola, F. Torti, P. J. Pfister, R. Dorent, and A. Corsini Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27Kip1/Cyclin E Expression Mol. Pharmacol., July 1, 2008; 74(1): 144 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Neukamm, A. A. Miyakawa, S. Y. Fukada, C. R. de Andrade, F. P. Pacheco, T. G. da Silva, L. N. Z. Ramalho, A. M. de Oliveira, and J. E. Krieger Original Research: Local TAT-p27Kip1 Fusion protein inhibits cell proliferation in rat Carotid arteries Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 129 - 136. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ishii, S.-i. Sakamoto, R. T. Kronengold, R. Virmani, E. A. Rivera, S. M. Goldman, E. J. Prechtel, J. G. Hill, and R. J. Damiano Jr. A novel bioengineered small-caliber vascular graft incorporating heparin and sirolimus: Excellent 6-month patency. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1237 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barilli, R. Visigalli, R. Sala, G. C. Gazzola, A. Parolari, E. Tremoli, S. Bonomini, A. Simon, E. I. Closs, V. Dall'Asta, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function Cardiovasc Res, June 1, 2008; 78(3): 563 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cheng, D. Tempel, A. Oostlander, F. Helderman, F. Gijsen, J. Wentzel, R. van Haperen, D. B. Haitsma, P. W. Serruys, A. F.W. van der Steen, et al. Rapamycin modulates the eNOS vs. shear stress relationship Cardiovasc Res, April 1, 2008; 78(1): 123 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Melikian and W Wijns Drug-eluting stents: a critique Heart, February 1, 2008; 94(2): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Ma, X. Z. Ruan, S. H. Powis, J. F. Moorhead, and Z. Varghese Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2721 - H2728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ishii, R. T. Kronengold, R. Virmani, E. A. Rivera, S. M. Goldman, E. J. Prechtel, R. B. Schuessler, and R. J. Damiano Jr Novel Bioengineered Small Caliber Vascular Graft With Excellent One-Month Patency Ann. Thorac. Surg., February 1, 2007; 83(2): 517 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Suttorp, G. J. Laarman, B. M. Rahel, J. C. Kelder, M. A.R. Bosschaert, F. Kiemeneij, J. M. ten Berg, E. T. Bal, B. J. Rensing, F. D. Eefting, et al. Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions Circulation, August 29, 2006; 114(9): 921 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fouty, T. Moss, V. Solodushko, and M. Kraft Dexamethasone can stimulate G1-S phase transition in human airway fibroblasts in asthma Eur. Respir. J., June 1, 2006; 27(6): 1160 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Stettler, S Allemann, M Egger, S Windecker, B Meier, and P Diem Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials Heart, May 1, 2006; 92(5): 650 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Rodriguez, J. F. Granada, M. Rodriguez-Alemparte, C. F. Vigo, J. Delgado, C. Fernandez-Pereira, A. Pocovi, A. M. Rodriguez-Granillo, D. Schulz, A. E. Raizner, et al. Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1522 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Roy-Chaudhury, V. P. Sukhatme, and A. K. Cheung Hemodialysis Vascular Access Dysfunction: A Cellular and Molecular Viewpoint J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1112 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sindermann, C. Kobbert, A. Skaletz-Rorowski, G. Breithardt, G. Plenz, and K. L. March Vascular injury response in mice is dependent on genetic background Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1307 - H1310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Serruys, M. J.B. Kutryk, and A. T.L. Ong Coronary-Artery Stents N. Engl. J. Med., February 2, 2006; 354(5): 483 - 495. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Lee, H.-C. Tan, and Y.-T. Lim Update on Drug-Eluting Stents for Prevention of Restenosis Asian Cardiovasc Thorac Ann, February 1, 2006; 14(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jaschke, C. Michaelis, S. Milz, M. Vogeser, T. Mund, L. Hengst, A. Kastrati, A. Schomig, and R. Wessely Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform Cardiovasc Res, December 1, 2005; 68(3): 483 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Morton, N. D. Arnold, J. Gunn, R. Varcoe, S. E. Francis, S. K. Dower, and D. C. Crossman Interleukin-1 receptor antagonist alters the response to vessel wall injury in a porcine coronary artery model Cardiovasc Res, December 1, 2005; 68(3): 493 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Stallone, B. Infante, A. Schena, M. Battaglia, P. Ditonno, A. Loverre, L. Gesualdo, F. P. Schena, and G. Grandaliano Rapamycin for Treatment of Chronic Allograft Nephropathy in Renal Transplant Patients J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3755 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Granada, D. Ensenat, A. N. Keswani, G. L. Kaluza, A. E. Raizner, X.-m. Liu, K. J. Peyton, M. A. Azam, H. Wang, and W. Durante Single Perivascular Delivery of Mitomycin C Stimulates p21 Expression and Inhibits Neointima Formation in Rat Arteries Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2343 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E Rodriguez, M Rodriguez Alemparte, C F Vigo, C Fernandez Pereira, C Llaurado, D Vetcher, A Pocovi, and J Ambrose Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial) Heart, November 1, 2005; 91(11): 1433 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Steffel, R. A. Latini, A. Akhmedov, D. Zimmermann, P. Zimmerling, T. F. Luscher, and F. C. Tanner Rapamycin, but Not FK-506, Increases Endothelial Tissue Factor Expression: Implications for Drug-Eluting Stent Design Circulation, September 27, 2005; 112(13): 2002 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sakakibara, B. Liu, S. Hollenbeck, and K. C. Kent Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2861 - H2868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. B. Mehrhof, R. Schmidt-Ullrich, R. Dietz, and C. Scheidereit Regulation of Vascular Smooth Muscle Cell Proliferation: Role of NF-{kappa}B Revisited Circ. Res., May 13, 2005; 96(9): 958 - 964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF]
|
|
|
|
|
|
J. F. LaDisa Jr., Lars. E. Olson, R. C. Molthen, D. A. Hettrick, P. F. Pratt, M. D. Hardel, J. R. Kersten, D. C. Warltier, and P. S. Pagel Alterations in wall shear stress predict sites of neointimal hyperplasia after stent implantation in rabbit iliac arteries Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2465 - H2475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fasciano, R. C. Patel, I. Handy, and C. V. Patel Regulation of Vascular Smooth Muscle Proliferation by Heparin: INHIBITION OF CYCLIN-DEPENDENT KINASE 2 ACTIVITY BY p27kip1 J. Biol. Chem., April 22, 2005; 280(16): 15682 - 15689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Hansson Inflammation, Atherosclerosis, and Coronary Artery Disease N. Engl. J. Med., April 21, 2005; 352(16): 1685 - 1695. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vignot, S. Faivre, D. Aguirre, and E. Raymond mTOR-targeted therapy of cancer with rapamycin derivatives Ann. Onc., April 1, 2005; 16(4): 525 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-W. Park, D.-H. Kim, H.-J. You, J.-J. Sir, S.-I. Jeon, S.-W. Youn, H.-M. Yang, C. Skurk, Y.-B. Park, K. Walsh, et al. Activated Forkhead Transcription Factor Inhibits Neointimal Hyperplasia After Angioplasty Through Induction of p27 Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 742 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fajadet, M.-C. Morice, C. Bode, P. Barragan, P. W. Serruys, W. Wijns, C. R. Constantini, J.-L. Guermonprez, H. Eltchaninoff, D. Blanchard, et al. Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial Circulation, March 1, 2005; 111(8): 1040 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Blaschke, O. Leppanen, Y. Takata, E. Caglayan, J. Liu, M. C. Fishbein, K. Kappert, K. I. Nakayama, A. R. Collins, E. Fleck, et al. Liver X Receptor Agonists Suppress Vascular Smooth Muscle Cell Proliferation and Inhibit Neointima Formation in Balloon-Injured Rat Carotid Arteries Circ. Res., December 10, 2004; 95(12): e110 - e123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Schwartz, N. A. Chronos, and R. Virmani Preclinical restenosis models and drug-eluting stents: Still important, still much to learn J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1373 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waksman, A. E. Ajani, A. D. Pichard, R. Torguson, E. Pinnow, D. Canos, L. F. Satler, K. M. Kent, P. Kuchulakanti, C. Pappas, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mukherjee, H. Huang, S. B. Petkova, C. Albanese, R. G. Pestell, V. L. Braunstein, G. J. Christ, M. Wittner, M. P. Lisanti, J. W. Berman, et al. Trypanosoma cruzi Infection Activates Extracellular Signal-Regulated Kinase in Cultured Endothelial and Smooth Muscle Cells Infect. Immun., September 1, 2004; 72(9): 5274 - 5282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Carter, M. Aggarwal, G. A Kopia, F. Tio, P. S Tsao, R. Kolata, A. C Yeung, G. Llanos, J. Dooley, and R. Falotico Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model Cardiovasc Res, September 1, 2004; 63(4): 617 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hausleiter, A. Kastrati, J. Mehilli, M. Vogeser, D. Zohlnhofer, H. Schuhlen, C. Goos, J. Pache, F. Dotzer, G. Pogatsa-Murray, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis: The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial Circulation, August 17, 2004; 110(7): 790 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Andres Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential Cardiovasc Res, July 1, 2004; 63(1): 11 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Schachner, Y. Zou, A. Oberhuber, A. Tzankov, T. Mairinger, G. Laufer, and J. O. Bonatti Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts Ann. Thorac. Surg., May 1, 2004; 77(5): 1580 - 1585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zohlnhofer, T. G. Nuhrenberg, F.-J. Neumann, T. Richter, A. E. May, R. Schmidt, K. Denker, M. A. Clauss, A. Schomig, and P. A. Baeuerle Rapamycin Effects Transcriptional Programs in Smooth Muscle Cells Controlling Proliferative and Inflammatory Properties Mol. Pharmacol., April 1, 2004; 65(4): 880 - 889. [Abstract] [Full Text]
|
|
|
|
|
|
E. Schampaert, E. A. Cohen, M. Schluter, F. Reeves, M. Traboulsi, L. M. Title, R. E. Kuntz, J. J. Popma, and the C-SIRIUS Investigators The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1110 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Mourani, P. J. Garl, J. M. Wenzlau, T. C. Carpenter, K. R. Stenmark, and M. C.M. Weiser-Evans Unique, Highly Proliferative Growth Phenotype Expressed by Embryonic and Neointimal Smooth Muscle Cells Is Driven by Constitutive Akt, mTOR, and p70S6K Signaling and Is Actively Repressed by PTEN Circulation, March 16, 2004; 109(10): 1299 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Lucchesi Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. Focus on "The mTOR/p70 S6K1 pathway regulates vascular smooth muscle differentiation" Am J Physiol Cell Physiol, March 1, 2004; 286(3): C480 - C481. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Martin, E. M. Rzucidlo, B. L. Merenick, D. C. Fingar, D. J. Brown, R. J. Wagner, and R. J. Powell The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation Am J Physiol Cell Physiol, March 1, 2004; 286(3): C507 - C517. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. C. Lopez-Talavera, A. Garcia-Ocana, I. Sipula, K. K. Takane, I. Cozar-Castellano, and A. F. Stewart Hepatocyte Growth Factor Gene Therapy for Pancreatic Islets in Diabetes: Reducing the Minimal Islet Transplant Mass Required in a Glucocorticoid-Free Rat Model of Allogeneic Portal Vein Islet Transplantation Endocrinology, February 1, 2004; 145(2): 467 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Moses, M. B. Leon, J. J. Popma, P. J. Fitzgerald, D. R. Holmes, C. O'Shaughnessy, R. P. Caputo, D. J. Kereiakes, D. O. Williams, P. S. Teirstein, et al. Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery N. Engl. J. Med., October 2, 2003; 349(14): 1315 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sindermann, C. Kobbert, F. Bauer, A. Skaletz-Rorowski, H. Hohage, G. Plenz, G. Breithardt, and K. L. March Vascular ligation response is independent of p107: stressing the role of the related p130 Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H915 - H918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mancini, S. Pinney, D. Burkhoff, J. LaManca, S. Itescu, E. Burke, N. Edwards, M. Oz, and A. R. Marks Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy Circulation, July 8, 2003; 108(1): 48 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Brara, M. Moussavian, M. A. Grise, J. P. Reilly, M. Fernandez, R. A. Schatz, and P. S. Teirstein Pilot Trial of Oral Rapamycin for Recalcitrant Restenosis Circulation, April 8, 2003; 107(13): 1722 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. de Graaf, R. Dammers, T. Vainas, A. P. G. Hoeks, and J. H. M. Tordoir Detection of cell-cycle regulators in failed arteriovenous fistulas for haemodialysis Nephrol. Dial. Transplant., April 1, 2003; 18(4): 814 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Diez-Juan and V. Andres Coordinate Control of Proliferation and Migration by the p27Kip1/Cyclin-Dependent Kinase/Retinoblastoma Pathway in Vascular Smooth Muscle Cells and Fibroblasts Circ. Res., March 7, 2003; 92(4): 402 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R Bennett IN-STENT STENOSIS: PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS Heart, February 1, 2003; 89(2): 218 - 224. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Tulis, Z. H. Mnjoyan, R. L. Schiesser, H. S. Shelat, A. J. Evans, P. Zoldhelyi, and K. Fujise Adenoviral Gene Transfer of Fortilin Attenuates Neointima Formation Through Suppression of Vascular Smooth Muscle Cell Proliferation and Migration Circulation, January 7, 2003; 107(1): 98 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Kim, K. A. Skelding, E. G. Nabel, and R. D. Simari What can cardiovascular gene transfer learn from genomics: and vice versa? Physiol Genomics, December 3, 2002; 11(3): 179 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Babapulle and M. J. Eisenberg Coated Stents for the Prevention of Restenosis: Part I Circulation, November 19, 2002; 106(21): 2734 - 2740. [Full Text] [PDF]
|
|
|
|
|
|
A. Farb, M. John, E. Acampado, F. D. Kolodgie, M. F. Prescott, and R. Virmani Oral Everolimus Inhibits In-Stent Neointimal Growth Circulation, October 29, 2002; 106(18): 2379 - 2384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Duda, B. Pusich, G. Richter, P. Landwehr, V. L. Oliva, A. Tielbeek, B. Wiesinger, J. B. Hak, H. Tielemans, G. Ziemer, et al. Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Six-Month Results Circulation, September 17, 2002; 106(12): 1505 - 1509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fuster, R. Corti, Z.A. Fayad, and J.J. Badimon Understanding the pathophysiology of the arterial wall: which method should we choose? Magnetic resonance imaging Eur. Heart J. Suppl., September 1, 2002; 4(suppl_F): F41 - F46. [Abstract] [PDF]
|
|
|
|
 |
|
 J. D. Morrisett, G. Abdel-Fattah, R. Hoogeveen, E. Mitchell, C. M. Ballantyne, H. J. Pownall, A. R. Opekun, J. S. Jaffe, S. Oppermann, and B. D. Kahan Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients J. Lipid Res., August 1, 2002; 43(8): 1170 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Morice, P. W. Serruys, J. E. Sousa, J. Fajadet, E. Ban Hayashi, M. Perin, A. Colombo, G. Schuler, P. Barragan, G. Guagliumi, et al. A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization N. Engl. J. Med., June 6, 2002; 346(23): 1773 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P W Serruys, E Regar, and A J Carter Rapamycin eluting stent: the onset of a new era in interventional cardiology Heart, April 1, 2002; 87(4): 305 - 307. [Full Text] [PDF]
|
|
|
|
|
|
H. C. Lowe, S. N. Oesterle, and L. M. Khachigian Coronary in-stent restenosis: Current status and future strategies J. Am. Coll. Cardiol., January 16, 2002; 39(2): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beyar and A. Roguin The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured? Eur. Heart J., November 2, 2001; 22(22): 2054 - 2057. [PDF]
|
|
|
|
|
|
B.J Rensing, J Vos, P.C Smits, D.P Foley, M.J.B.M van den Brand, W.J van der Giessen, P.J de Feijter, and P.W Serruys Coronary restenosis elimination with a sirolimus eluting stent; First European human experience with 6-month angiographic and intravascular ultrasonic follow-up Eur. Heart J., November 2, 2001; 22(22): 2125 - 2130. [Abstract] [PDF]
|
|
|
|
|
|
P. S. Teirstein Living the Dream of No Restenosis Circulation, October 23, 2001; 104(17): 1996 - 1998. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, M. A. Costa, A. C. Abizaid, B. J. Rensing, A. S. Abizaid, L. F. Tanajura, K. Kozuma, G. Van Langenhove, A. G.M.R. Sousa, R. Falotico, et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up Circulation, October 23, 2001; 104(17): 2007 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki, G. Kopia, S.-i. Hayashi, L. R. Bailey, G. Llanos, R. Wilensky, B. D. Klugherz, G. Papandreou, P. Narayan, M. B. Leon, et al. Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model Circulation, September 4, 2001; 104(10): 1188 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. DIEZ-JUAN and V. ANDRES The growth suppressor p27Kip1 protects against diet-induced atherosclerosis FASEB J, September 1, 2001; 15(11): 1989 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Marx and A. R. Marks Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis Circulation, August 21, 2001; 104(8): 852 - 855. [Full Text] [PDF]
|
|
|
|
|
|
T. S. Mahoney, A. S. Weyrich, D. A. Dixon, T. McIntyre, S. M. Prescott, and G. A. Zimmerman Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes PNAS, August 17, 2001; (2001) 181201398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Braun-Dullaeus, M. J. Mann, U. Seay, L. Zhang, H. E. von der Leyen, R. E. Morris, and V. J. Dzau Cell Cycle Protein Expression in Vascular Smooth Muscle Cells In Vitro and In Vivo Is Regulated Through Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1152 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Boehm and E. G. Nabel Cell Cycle and Cell Migration : New Pieces to the Puzzle Circulation, June 19, 2001; 103(24): 2879 - 2881. [Full Text] [PDF]
|
|
|
|
|
|
J. Sun, S. O. Marx, H.-J. Chen, M. Poon, A. R. Marks, and L. E. Rabbani Role for p27Kip1 in Vascular Smooth Muscle Cell Migration Circulation, June 19, 2001; 103(24): 2967 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sriram and C. Patterson Cell Cycle in Vasculoproliferative Diseases : Potential Interventions and Routes of Delivery Circulation, May 15, 2001; 103(19): 2414 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wakino, U. Kintscher, S. Kim, S. Jackson, F. Yin, S. Nagpal, R. A. S. Chandraratna, W. A. Hsueh, and R. E. Law Retinoids Inhibit Proliferation of Human Coronary Smooth Muscle Cells by Modulating Cell Cycle Regulators Arterioscler. Thromb. Vasc. Biol., May 1, 2001; 21(5): 746 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zohlnhofer, C. A. Klein, T. Richter, R. Brandl, A. Murr, T. Nuhrenberg, A. Schomig, P. A. Baeuerle, and F.-J. Neumann Gene Expression Profiling of Human Stent-Induced Neointima by cDNA Array Analysis of Microscopic Specimens Retrieved by Helix Cutter Atherectomy : Detection of FK506-Binding Protein 12 Upregulation Circulation, March 13, 2001; 103(10): 1396 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. NISHIMURA, J. L. FAUL, G. J. BERRY, I. VEVE, R. G. PEARL, and P. N. KAO 40-O-(2-Hydroxyethyl)-rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 498 - 502. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Sousa, M. A. Costa, A. Abizaid, A. S. Abizaid, F. Feres, I. M. F. Pinto, A. C. Seixas, R. Staico, L. A. Mattos, A. G. M. R. Sousa, et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study Circulation, January 16, 2001; 103(2): 192 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kawauchi, J.-i. Suzuki, R. Morishita, Y. Wada, A. Izawa, N. Tomita, J. Amano, Y. Kaneda, T. Ogihara, S. Takamoto, et al. Gene Therapy for Attenuating Cardiac Allograft Arteriopathy Using Ex Vivo E2F Decoy Transfection by HVJ-AVE-Liposome Method in Mice and Nonhuman Primates Circ. Res., November 24, 2000; 87(11): 1063 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D. Kolodgie, A. Farb, and R. Virmani Local Delivery of Ceramide for Restenosis : Is There a Future for Lipid Therapy? Circ. Res., August 18, 2000; 87(4): 264 - 267. [Full Text] [PDF]
|
|
|
|
|
|
U. Kintscher, S. Wakino, S. Kim, S. M. Jackson, E. Fleck, W. A. Hsueh, and R. E. Law Doxazosin Inhibits Retinoblastoma Protein Phosphorylation and G1->S Transition in Human Coronary Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1216 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Peiretti, S. Lopez, P. Deprez-Beauclair, B. Bonardo, I. Juhan-Vague, and G. Nalbone Inhibition of p70S6 Kinase during Transforming Growth Factor-beta 1/Vitamin D3-induced Monocyte Differentiation of HL-60 Cells Allows Tumor Necrosis Factor-alpha to Stimulate Plasminogen Activator Inhibitor-1 Synthesis J. Biol. Chem., August 17, 2001; 276(34): 32214 - 32219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zhao, J. Letterman, and B. M. Schreiber beta -Migrating Very Low Density Lipoprotein (beta VLDL) Activates Smooth Muscle Cell Mitogen-activated Protein (MAP) Kinase via G Protein-coupled Receptor-mediated Transactivation of the Epidermal Growth Factor (EGF) Receptor. EFFECT OF MAP KINASE ACTIVATION ON beta VLDL PLUS EGF-INDUCED CELL PROLIFERATION J. Biol. Chem., August 10, 2001; 276(33): 30579 - 30588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Mahoney, A. S. Weyrich, D. A. Dixon, T. McIntyre, S. M. Prescott, and G. A. Zimmerman Cell adhesion regulates gene expression at translational checkpoints in human myeloid leukocytes PNAS, August 28, 2001; 98(18): 10284 - 10289. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||